Drug Profile
CP 471474
Latest Information Update: 23 Jul 2002
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Nonindustrial source; Pfizer
- Class Anti-ischaemics
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Myocardial infarction
Most Recent Events
- 23 Jun 2000 Pfizer has merged with Warner-Lambert
- 18 Apr 2000 Profile reviewed but no significant changes have been made
- 08 Jun 1999 New profile